Ignite Creation Date:
2025-12-24 @ 12:59 PM
Ignite Modification Date:
2026-01-26 @ 3:18 AM
Study NCT ID:
NCT03399461
Status:
COMPLETED
Last Update Posted:
2019-03-14
First Post:
2018-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014923', 'term': 'Wiskott-Aldrich Syndrome'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}], 'ancestors': [{'id': 'D025861', 'term': 'Blood Coagulation Disorders, Inherited'}, {'id': 'D001778', 'term': 'Blood Coagulation Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D008231', 'term': 'Lymphopenia'}, {'id': 'D007970', 'term': 'Leukopenia'}, {'id': 'D000095542', 'term': 'Cytopenia'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D007960', 'term': 'Leukocyte Disorders'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D040181', 'term': 'Genetic Diseases, X-Linked'}, {'id': 'D000081207', 'term': 'Primary Immunodeficiency Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011795', 'term': 'Surveys and Questionnaires'}], 'ancestors': [{'id': 'D003625', 'term': 'Data Collection'}, {'id': 'D004812', 'term': 'Epidemiologic Methods'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D017531', 'term': 'Health Care Evaluation Mechanisms'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}, {'id': 'D011634', 'term': 'Public Health'}, {'id': 'D004778', 'term': 'Environment and Public Health'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 19}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-01-24', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-03', 'completionDateStruct': {'date': '2018-09-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-03-13', 'studyFirstSubmitDate': '2018-01-08', 'studyFirstSubmitQcDate': '2018-01-08', 'lastUpdatePostDateStruct': {'date': '2019-03-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-01-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-09-14', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of subject reported perspectives on WAS', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on WAS.'}, {'measure': 'Number of caregiver reported perspectives on WAS', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in caregivers of subjects with WAS to understand their perspective on WAS.'}, {'measure': 'Number of subject reported preventative measures taken to avoid infection and bleeding', 'timeFrame': 'Up to 90 minutes', 'description': 'The preventative measures taken to avoid infection and bleeding as reported by subjects during open-ended interviews will be summarized.'}, {'measure': 'Number of caregiver reported preventative measures taken to avoid infection and bleeding', 'timeFrame': 'Up to 90 minutes', 'description': 'The preventative measures taken to avoid infection and bleeding as reported by caregivers during open-ended interviews will be summarized.'}, {'measure': 'Number of subject reported awareness on the risk of disease', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in adolescent and adult subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).'}, {'measure': 'Number of caregiver reported awareness on the risk of disease', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in caregivers of WAS subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).'}, {'measure': 'Number of treatment sequences received by subjects', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted to understand the treatments received by subjects in terms of sequencing.'}, {'measure': 'Number of subject reported reasons for discontinuation or change in treatment option', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in adolescent and adult subjects to understand reasons for discontinuation or change in treatment option for WAS.'}, {'measure': 'Number of caregiver reported reasons for discontinuation or change in treatment option', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in caregivers of WAS subjects to understand reasons for discontinuation or change in treatment option for WAS.'}, {'measure': 'Analysis of tolerability of treatment by subjects', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in subjects and caregivers to understand the tolerability of WAS treatment by subjects.'}, {'measure': 'Number of subject reported treatment burden', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in adolescent and adult subjects to analyze treatment burden for subjects.'}, {'measure': 'Number of caregiver reported treatment burden', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in caregivers of WAS subjects to analyze treatment burden for caregivers.'}, {'measure': 'Number of subject reported perspectives on the risk associated with treatment', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on the risks associated with each treatment.'}, {'measure': 'Number of caregiver reported perspectives on the risk associated with treatment', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted in caregivers of WAS subjects to understand their perspective on the risks associated with each treatment.'}, {'measure': 'Number of key concepts of interest', 'timeFrame': 'Up to 90 minutes', 'description': 'Open-ended interviews will be conducted to identify the important concepts of interest that may be used in future clinical trials.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['United States', 'United Kingdom', 'Wiskott-Aldrich Syndrome', 'Caregiver', 'Interview', 'immune deficiency', 'France'], 'conditions': ['Wiskott-Aldrich Syndrome']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.gsk-studyregister.com/study/6052', 'label': 'Results for study 208034 can be found on the GSK Clinical Study Register.'}]}, 'descriptionModule': {'briefSummary': 'WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '30 Years', 'minimumAge': '12 Years', 'genderBased': True, 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'A convenience sample of approximately, 21 subjects with WAS and primary caregivers of WAS subjects will be included in the study.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nSubjects:\n\n* Male adolescents or young adults ranging in age from 12 through 30 years old.\n* Diagnosis of WAS defined by WAS genetic mutation with a clinical score \\>=1 or self-reported disease severity.\n* Subjects who are "conservatively managed" or have not received treatment for WAS; a maximum of 5 subjects who have received a hematopoietic stem cell transplant within the preceding two years.\n* Able to read, speak, and understand English or French sufficiently to complete all assessments.\n* Willing and able to participate in an audio-recorded, telephone or video conference session, including adherence to the interview instructions and completion of all questionnaires.\n* Parent/guardian/patient signed informed consent.\n\nCaregivers:\n\n* Caregivers of children \\>=2 years of age diagnosed with WAS; at least 5 caregivers of subjects under the age of 8.\n* Caregivers of subjects with a diagnosis of WAS defined by WAS genetic mutation with a clinical score \\>=1 or self-reported disease severity.\n* Caregivers of subjects who are "conservatively managed" or have not received treatment for WAS; At least 2 caregivers of subjects who have received a hematopoietic stem cell transplant within the preceding two years.\n* Caregivers are defined as primary caregiver.\n* Able to read, speak, and understand English or French sufficiently to complete all assessments.\n* Willing and able to participate in an audio-recorded, telephone or video conferencing interview session, including adherence to the interview instructions and completion of all questionnaires.\n* Caregivers of Wiskott-Aldrich patients can be of any age or gender and do not have to follow the patient inclusion criteria, as long as their child/patient meets the inclusion criteria, as outlined.\n\nExclusion Criteria:\n\nSubjects\n\n* Subjects who have previously received gene therapy treatment Caregivers\n* Caregivers of subjects who have previously received gene therapy treatment\n* Professional caregivers (that is, at home nurse or equivalent).'}, 'identificationModule': {'nctId': 'NCT03399461', 'briefTitle': 'Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)', 'organization': {'class': 'INDUSTRY', 'fullName': 'GlaxoSmithKline'}, 'officialTitle': 'Understanding of the Patient and Caregiver Experience of Wiskott-Aldrich Syndrome (WAS)', 'orgStudyIdInfo': {'id': '208034'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group 1', 'description': 'Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.', 'interventionNames': ['Other: Patient Interview guide', 'Other: Sociodemographic questionnaire', 'Other: Pediatric quality of life (PedsQL) questionnaire', 'Other: Clinical questionnaire']}, {'label': 'Group 2', 'description': 'Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.', 'interventionNames': ['Other: Caregiver interview guide', 'Other: Sociodemographic questionnaire', 'Other: Pediatric quality of life (PedsQL) questionnaire', 'Other: Clinical questionnaire']}, {'label': 'Group 3', 'description': 'Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.', 'interventionNames': ['Other: Caregiver interview guide', 'Other: Sociodemographic questionnaire', 'Other: Pediatric quality of life (PedsQL) questionnaire', 'Other: Clinical questionnaire']}], 'interventions': [{'name': 'Patient Interview guide', 'type': 'OTHER', 'description': 'The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.', 'armGroupLabels': ['Group 1']}, {'name': 'Caregiver interview guide', 'type': 'OTHER', 'description': 'The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.', 'armGroupLabels': ['Group 2', 'Group 3']}, {'name': 'Sociodemographic questionnaire', 'type': 'OTHER', 'description': 'At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.', 'armGroupLabels': ['Group 1', 'Group 2', 'Group 3']}, {'name': 'Pediatric quality of life (PedsQL) questionnaire', 'type': 'OTHER', 'description': 'The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.', 'armGroupLabels': ['Group 1', 'Group 2', 'Group 3']}, {'name': 'Clinical questionnaire', 'type': 'OTHER', 'description': 'At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.', 'armGroupLabels': ['Group 1', 'Group 2', 'Group 3']}]}, 'contactsLocationsModule': {'locations': [{'zip': '19426', 'city': 'Collegeville', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 40.18566, 'lon': -75.45157}}], 'overallOfficials': [{'name': 'GSK Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'GlaxoSmithKline'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}